AADCLL2: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Diseases

Target Name: AADACL2

NCBI ID: G344752

AADACL2

Other Name(s): ADCL2_HUMAN | Arylacetamide deacetylase like 2 | Arylacetamide deacetylase-like 2 | arylacetamide deacetylase-like 2 | arylacetamide deacetylase like 2

AADCLL2: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Diseases

AADACL2 (ADCL2-HUMAN) is a protein that is expressed in various tissues of the human body. It is a member of the AADC family, which includes proteins that are involved in the intracellular signaling pathway known as the adaptor protein signaling pathway. This pathway is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival.

AADCLL2 (ADCL2) is a protein that is derived from the human ADCL2 gene. It is a 21-kDa protein that is expressed in various tissues of the human body, including the brain, heart, liver, and muscle. AADCLL2 is involved in the regulation of cellular processes, including cell signaling, DNA replication, and apoptosis.

AADCLL2 is a potential drug target or biomarker because of its involvement in various cellular processes that are crucial for human health and disease. As a drug target, AADCLL2 may be used to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. As a biomarker, AADCLL2 may be used to diagnose and monitor various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Structure and Function

The AADCLL2 protein is a member of the AADC family, which includes proteins that are involved in the regulation of various cellular processes, including cell signaling, DNA replication, and apoptosis. AADCLL2 is a 21-kDa protein that consists of 101 amino acid residues. It has a molecular weight of 19,312 Da and a calculated pI of 6.5.

AADCLL2 is involved in various cellular processes, including cell signaling, DNA replication, and apoptosis. It is a component of the DNAsome complex, which is responsible for the regulation of DNA replication and gene expression. It is also involved in the regulation of cell apoptosis, which is a natural process that is involved in the elimination of damaged or dysfunctional cells.

AADCLL2 is involved in the regulation of cellular processes that are crucial for human health and disease. As a drug target, AADCLL2 may be used to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. As a biomarker, AADCLL2 may be used to diagnose and monitor various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Drug Treatment

AADCLL2 is a potential drug target or biomarker that can be used to treat various diseases. As a drug target, AADCLL2 may be used to treat cancer, neurodegenerative diseases, and autoimmune diseases.

AADCLL2 has been shown to be involved in the regulation of cellular processes that are crucial for human health and disease. Studies have shown that AADCLL2 is involved in the regulation of cell signaling, DNA replication, and apoptosis. It is also involved in the regulation of cellular processes that are crucial for the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

As a drug target, AADCLL2 may be used to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, AADCLL2 has been shown to be involved in the regulation of the development and progression of various cancers, including breast cancer, lung cancer, and colorectal cancer.

In addition to its involvement in cancer, AADCLL2 is also involved in the regulation of neurodegenerative diseases and autoimmune diseases. For example, AADCLL2 has been shown to be involved in the regulation of the development and progression of Alzheimer's disease, a neurodegenerative disease. It is also involved in the regulation of the development and progression of autoimmune diseases,

Protein Name: Arylacetamide Deacetylase Like 2

The "AADACL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AADACL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets